|

PRISM: Patient Experiences With PET Imaging in Prostate Cancer

RECRUITINGSponsored by Yale University
Actively Recruiting
SponsorYale University
Started2024-07-25
Est. completion2028-07
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations7 sites

Summary

The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic cancer earlier and more reliably.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Documented diagnosis of prostate cancer
* Scheduled for their FIRST PSMA PET scan for prostate cancer
* English-speaking
* Willing and able to complete 4 surveys electronically or on paper at 3 timepoints (within 1 month after PET scan, 3-6 months, 12 months)
* Able to use mobile device (smartphone or tablet) or computer with web access to complete study surveys or able to complete paper surveys

Exclusion Criteria:

* Lack of access to a mobile device (smartphone or tablet) or computer with web access or unable to receive surveys by mail.
* Unable to give consent and be enrolled
* PET scan is being conducted within a clinical trial

Conditions2

CancerProstate Cancer

Locations7 sites

Yale New Haven Health Bridgeport Hospital - Park Ave Medical Center
Bridgeport, Connecticut, 06611
Griffin Hospital
Derby, Connecticut, 06418
Yale New Haven Health Greenwich Hospital
Greenwich, Connecticut, 06830
Radiology and Biomedical Imaging - New Haven - Smilow Cancer Hospital (North Pavilion):
New Haven, Connecticut, 06520
Saint Raphael's Radiology and Biomedical Imaging, Basement Location.
New Haven, Connecticut, 06520

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.